Research Group: Marialaura Amadio

The main interest is for the Nrf2 factor and the RNA-binding HuR/ELAV protein, both involved in the cytoprotective response against oxidative stress, inflammation, and protein clearance impairment. The aim is to understand the role of these proteins in physio-pathological contexts. The research includes the pharmacological modulation of Nrf2 and ELAV as potential therapeutic targets in pathologies of the retina and other body districts.
A study of the biological signature and effects of retinal pigment epithelium-derived extracellular vesicles, a potential cytoprotective multichannel message among specialized eye cells, is also ongoing.

Recent Publications:

• Manai F, Smedowski A, Kaarniranta K, Comincini S, Amadio M. Extracellular vesicles in degenerative retinal diseases: A new therapeutic paradigm. J Control Release. 2024 Jan; 365:448-468. doi: 10.1016/j.jconrel.2023.11.035. PMID: 38013069.
• Bresciani G, Manai F, Davinelli S, Tucci P, Saso L, Amadio M. Novel potential pharmacological applications of dimethyl fumarate-an overview and update. Front Pharmacol. 2023 Sep; 14:1264842. doi: 10.3389/fphar.2023.1264842. PMID: 37745068; PMCID: PMC10512734.
• Pacwa A, Machowicz J, Akhtar S, Rodak P, Liu X, Pietrucha-Dutczak M, Lewin-Kowalik J, Amadio M, Smedowski A. Deficiency of the RNA-binding protein ELAVL1/HuR leads to the failure of endogenous and exogenous neuroprotection of retinal ganglion cells. Front Cell Neurosci. 2023 Feb; 17:1131356. doi: 10.3389/fncel.2023.1131356. PMID: 36874215; PMCID: PMC9982123.

Links:
https://www.researchgate.net/profile/Marialaura_Amadio